Abstract
The aim of this study was to evaluate the prognostic impact of pretreatment neutrophils, previously rendered statistically independent, on the response and on long-term survival of metastatic renal carcinoma patients treated with outpatient subcutaneous (s.c.) interleukin-2 (IL-2) and s.c. interferon (IFN)-alpha. We assessed a total of 495 patients receiving s.c. IL-2/s.c. IFN-alpha-based therapy. While 417 patients with neutrophil counts <6500 cells/microL at baseline achieved 30% objective responses and a median survival of 22 months, 78 patients with pretreatment neutrophil counts >or= 6500 cells/microL had 18% objective responses and a median survival of 9 months (p=0.0000). In conclusion, pretreatment peripheral blood neutrophils <6500/microL constitute an immunologic predictor of tumor response and long-term survival in metastatic renal-cell carcinoma patients treated with s.c. IL-2 and s.c. IFN-alpha-based regimens.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / therapeutic use
-
Antiviral Agents / therapeutic use
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / immunology
-
Bone Neoplasms / secondary
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / immunology
-
Brain Neoplasms / secondary
-
Carcinoma, Renal Cell / immunology
-
Carcinoma, Renal Cell / secondary
-
Carcinoma, Renal Cell / therapy*
-
Chemotherapy, Adjuvant
-
Drug Therapy, Combination
-
Female
-
Humans
-
Immunotherapy*
-
Interferon-alpha / therapeutic use
-
Interleukin-2 / therapeutic use
-
Kidney Neoplasms / immunology
-
Kidney Neoplasms / pathology
-
Kidney Neoplasms / therapy*
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / immunology
-
Liver Neoplasms / secondary
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / immunology
-
Lung Neoplasms / secondary
-
Lymphatic Metastasis
-
Lymphocytes, Tumor-Infiltrating
-
Male
-
Middle Aged
-
Neutrophils / immunology*
-
Prognosis
-
Survival Rate
Substances
-
Antineoplastic Agents
-
Antiviral Agents
-
Interferon-alpha
-
Interleukin-2